论文部分内容阅读
目的 :评价卡铂注射液对肺癌和乳腺癌的疗效及安全性。方法 :选择 5 3例肺癌和乳腺癌患者 ,可评价患者 5 1例 ,初治 44例 ,复治 7例 ,随机分成卡铂注射液研究组 35例 ,卡铂粉针剂对照组 16例。治疗方案分别为肺癌组 :d1,卡铂 30 0mg/m2 ,静滴 ;d3～ 7,依托泊苷 6 0mg/m2 静滴 ;d2～ 6 ,异环磷酰胺 1.5g/m2 ,静滴。乳腺癌组 :d1,卡铂 30 0mg/m2 ,静滴 ;d2 ,阿霉素 40mg/m2 或表阿霉素 5 0mg/m2 静滴 ;d4～ 7,氟尿嘧啶 35 0mg/m2 静滴。 2 8d为 1周期 ,至少治疗 2周期。结果 :卡铂注射液组的总有效率为 6 2 .9% (2 2 /35 ) ,主要不良反应为骨髓抑制、白细胞、血小板和血红蛋白减少。结论 :卡铂注射液对肺癌、乳腺癌疗效肯定 ,毒性可以耐受
Objective: To evaluate the efficacy and safety of carboplatin in lung cancer and breast cancer. Methods: Totally 53 patients with lung cancer and breast cancer were enrolled in this study. Fifty-one patients were evaluated, of whom 44 patients were initially treated and 7 patients were retreated. All patients were randomly divided into carboplatin injection group (35 cases) and carboplatin injection group (16 cases). Treatment regimens were lung cancer group: d1, carboplatin 30 0mg / m2, intravenous drip; d3 ~ 7, etoposide 60mg / m2 intravenous; d2 ~ 6, ifosfamide 1.5g / m2, intravenous infusion. Breast cancer group: d1, carboplatin 30 0mg / m2, intravenous drip; d2, adriamycin 40mg / m2 or epirubicin 50mg / m2 intravenous; d4 ~ 7, fluorouracil 35 0mg / m2 intravenous infusion. 2 8d for a period of at least two cycles of treatment. Results: The total effective rate of carboplatin injection group was 62.9% (2/35). The main adverse reactions were myelosuppression, leucocyte, platelet and hemoglobin. Conclusion: Carboplatin injection has positive curative effect on lung cancer and breast cancer and its toxicity can be tolerated